[ { "assumptions": [ "Open-label, single-arm design with interim, non-prespecified analyses.", "Efficacy analyses focused on full-dose recipients with >=12 months follow-up.", "Portal vein infusion and glucocorticoid-free immunosuppression are integral to treatment effect and safety profile." ], "authors": [ "T.W. Reichman", "J.F. Markmann", "J. Odorico", "P. Witkowski", "J.J. Fung", "M. Wijkstrom", "F. Kandeel", "E.J.P. de Koning", "A.L. Peters", "C. Mathieu", "L.S. Kean", "B.G. Bruinsma", "C. Wang", "M. Mascia", "B. Sanna", "G. Marigowda", "F. Pagliuca", "D. Melton", "C. Ricordi", "M.R. Rickels", "VX-880-101 FORWARD Study Group" ], "citation": "T.W. Reichman; J.F. Markmann; J. Odorico et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. New England Journal of Medicine (2025). https://doi.org/10.1056/NEJMoa2506549", "claims": [ "All participants had undetectable C-peptide at baseline and detectable C-peptide after infusion, indicating engraftment.", "All 12 full-dose participants were free of severe hypoglycemia and had HbA1c <7% at day 365, with >70% CGM time-in-range.", "Ten of 12 full-dose participants achieved insulin independence at day 365.", "Neutropenia was the most common serious adverse event; two deaths occurred during follow-up." ], "conclusions": [ "Zimislecel can restore physiologic islet function and improve glycemic control in high-risk T1D, supporting further clinical investigation." ], "contributions": [ "First clinical report of fully differentiated stem-cell-derived islet therapy (zmislecel) in T1D with portal vein delivery.", "Defines efficacy endpoints tied to severe hypoglycemia elimination and HbA1c improvement.", "Provides early safety profile including serious adverse events and mortality in this setting." ], "future_work": [ "Longer-term follow-up to assess durability and late safety events.", "Larger, possibly comparative trials to contextualize outcomes versus historical controls." ], "key_equations": [ "Primary endpoint (part C): SHE-free in days 90-365 AND (HbA1c < 7% OR delta HbA1c <= -1% from baseline at >=1 visit between days 180-365).", "Secondary endpoint: peak C-peptide >= 100 pmol/L during 4-hour MMTT (functional graft threshold).", "Severe hypoglycemic event: assistance required AND (glucose < 54 mg/dL OR prompt recovery after carbohydrate/IV glucose/glucagon).", "Target CGM range: 70-180 mg/dL." ], "limitations": [ "Small sample size and open-label, single-group design limit causal inference.", "Interim analyses were not prespecified and follow-up is short for durability and long-term safety.", "Immunosuppression-related risks confound safety interpretation." ], "source_type": "paper", "summary": "Phase 1-2 open-label trial of zimislecel (VX-880), a stem-cell-derived islet therapy delivered by portal vein infusion with glucocorticoid-free immunosuppression, in adults with type 1 diabetes and recurrent severe hypoglycemia. Reports engraftment by MMTT C-peptide, elimination of severe hypoglycemia, improved HbA1c and CGM time-in-range, and insulin independence rates at 12 months, alongside safety outcomes including neutropenia and two deaths.", "title": "Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes", "url": "https://doi.org/10.1056/NEJMoa2506549", "venue": "New England Journal of Medicine", "year": 2025 }, { "assumptions": [ "Single-arm design deemed acceptable due to ethical concerns and FDA guidance.", "Participants had failed expert management and had persistent IAH/SHEs.", "Portal vein infusion and immunosuppression are required to achieve graft function." ], "authors": [ "Bernhard J. Hering", "William R. Clarke", "Nancy D. Bridges", "Thomas L. Eggerman", "Rodolfo Alejandro", "Melena D. Bellin", "Kathryn Chaloner", "Christine W. Czarniecki", "Julia S. Goldstein", "Lawrence G. Hunsicker", "Dixon B. Kaufman", "Olle Korsgren", "Christian P. Larsen", "Xunrong Luo", "James F. Markmann", "Ali Naji", "Jose Oberholzer", "Andrew M. Posselt", "Michael R. Rickels", "Camillo Ricordi", "Mark A. Robien", "Peter A. Senior", "A.M. James Shapiro", "Peter G. Stock", "Nicole A. Turgeon", "Clinical Islet Transplantation Consortium" ], "citation": "Bernhard J. Hering; William R. Clarke; Nancy D. Bridges et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care (2016). https://doi.org/10.2337/dc15-1988", "claims": [ "87.5% achieved the primary endpoint at 1 year and 71% at 2 years.", "Median HbA1c decreased to ~5.6% at 1 year with major reductions in SHEs.", "Insulin independence achieved in 52% at day 365; C-peptide >0.3 ng/mL in most participants.", "Renal function declined over time; bleeding occurred in a subset of portal vein cannulations." ], "conclusions": [ "PHPI transplantation effectively restores glycemic control and eliminates severe hypoglycemia in high-risk T1D, with manageable but significant procedure/immunosuppression risks." ], "contributions": [ "Establishes efficacy and safety profile of PHPI transplantation in severe hypoglycemia cohort.", "Standardizes composite endpoint and insulin-independence criteria for regulatory use.", "Provides detailed safety outcomes, including renal function changes and procedure-related bleeding." ], "future_work": [ "Long-term follow-up to assess durability and kidney safety.", "Improved immunosuppressive or tolerogenic regimens to reduce toxicity." ], "key_equations": [ "Primary endpoint: HbA1c < 7.0% at day 365 AND freedom from SHEs from day 28 to day 365 after first transplant.", "Insulin independence (7-day criteria): HbA1c < 7.0%, fasting capillary glucose >140 mg/dL <=3 times, fasting serum glucose <126 mg/dL, MMTT glucose <180 mg/dL at 90 min, and >=1 C-peptide >=0.5 ng/mL.", "Functional graft: basal or stimulated C-peptide >0.3 ng/mL.", "Dose thresholds: >5,000 IEQ/kg first dose; >=4,000 IEQ/kg subsequent doses." ], "limitations": [ "Open-label single-arm design without concurrent controls.", "Missing data and participant withdrawals at later timepoints.", "Immunosuppression-related adverse effects limit generalizability." ], "source_type": "paper", "summary": "License-enabling phase 3 single-arm trial (CIT-07) of purified human pancreatic islet (PHPI) transplantation in T1D with impaired awareness of hypoglycemia and severe hypoglycemic events. Demonstrates high rates of composite endpoint success, improved HbA1c, restored hypoglycemia awareness, and meaningful C-peptide graft function, while documenting procedure and immunosuppression risks including bleeding and renal function decline.", "title": "Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia", "url": "https://doi.org/10.2337/dc15-1988", "venue": "Diabetes Care", "year": 2016 }, { "assumptions": [ "Consensus-based recommendations derived from available studies and expert vote.", "Targets are population-level guidance requiring individualization.", "TIR associations with outcomes are inferred from observational and retrospective analyses." ], "authors": [ "Tadej Battelino", "et al." ], "citation": "Tadej Battelino; et al. et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care (2019). https://doi.org/10.2337/dci19-0028", "claims": [ "TIR of 70% corresponds roughly to HbA1c around 7% in adults.", "Each 10% increase in TIR is associated with ~0.5% to 0.8% HbA1c reduction depending on dataset.", "Consensus targets define ranges and time goals for multiple diabetes populations." ], "conclusions": [ "TIR-based targets provide actionable CGM endpoints that complement HbA1c in clinical trials and care." ], "contributions": [ "Standardizes CGM reporting metrics and targets used in clinical trials and practice.", "Defines TIR/TBR/TAR targets that can be mapped to HbA1c for interpretation.", "Sets minimum data completeness requirements for reliable CGM interpretation." ], "future_work": [ "Long-term trials validating TIR targets against clinical outcomes.", "Refinement of targets for special populations with more evidence." ], "key_equations": [ "TIR target (T1D/T2D): >70% in 70-180 mg/dL; TBR <4% (<70 mg/dL) and <1% (<54 mg/dL); TAR <25% (>180 mg/dL) and <5% (>250 mg/dL).", "Older/high-risk targets: TIR >50% (70-180 mg/dL), TBR <1% (<70 mg/dL), TAR <10% (>250 mg/dL).", "Data sufficiency: >=14 days CGM with >=70% data capture.", "Glycemic variability target: %CV <=36%." ], "limitations": [ "Evidence linking TIR to long-term outcomes remains limited.", "Targets may not be achievable in all populations and require personalization." ], "source_type": "paper", "summary": "International consensus report defining standardized CGM metrics and clinical targets for time in range (TIR), time below range (TBR), time above range (TAR), data sufficiency, and glycemic variability. Provides numeric thresholds for different populations and links TIR to A1c and complication risk, enabling standardized interpretation of CGM endpoints in trials.", "title": "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range", "url": "https://doi.org/10.2337/dci19-0028", "venue": "Diabetes Care", "year": 2019 }, { "assumptions": [ "Minimal model estimates (oral glucose minimal model and C-peptide kinetics) are valid for MMTT-derived parameters.", "Standardized meal composition and sampling schedule are feasible across centers.", "Obese cohorts represent the intended glucose tolerance strata." ], "authors": [ "Sudha S. Shankar", "Adrian Vella", "Ralph H. Raymond", "Myrlene A. Staten", "Roberto A. Calle", "Richard N. Bergman", "Charlie Cao", "Danny Chen", "Claudio Cobelli", "Chiara Dalla Man", "Mark Deeg", "Jennifer Q. Dong", "Douglas S. Lee", "David Polidori", "R. Paul Robertson", "Hartmut Ruetten", "Darko Stefanovski", "Maria T. Vassileva", "Gordon C. Weir", "David A. Fryburg" ], "citation": "Sudha S. Shankar; Adrian Vella; Ralph H. Raymond et al. Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of Beta-Cell Function. Diabetes Care (2016). https://doi.org/10.2337/dc15-0931", "claims": [ "MMTT and AST measures show good to very good reproducibility with ICCs varying by metric and population.", "Standardized meal (470 kcal; 66% carb, 18% fat, 16% protein) and sampling schedule are specified.", "DI declines progressively from NGT to PDM to T2DM in this cohort." ], "conclusions": [ "Standardized MMTT and AST are reproducible and complementary for beta-cell function assessment in clinical trials." ], "contributions": [ "Defines standardized MMTT and AST protocols with reproducibility metrics.", "Provides operational details (meal composition, sampling timing) for trial use.", "Quantifies ICC-based reproducibility for key beta-cell metrics." ], "future_work": [ "Apply standardized protocols in interventional trials across additional populations.", "Evaluate performance for specific therapeutic effects." ], "key_equations": [ "Disposition index: DI = Si * Phi_tot (beta-cell responsivity).", "AIRg = AUC of insulin above basal from 0-10 min after IV glucose.", "AIRarg = mean of top 3 insulin values (2-5 min) minus basal insulin.", "AIRargMAX = mean of top 3 insulin values (62-65 min) minus basal at elevated glucose.", "ISR = AIRargMAX - AIRarg." ], "limitations": [ "Study populations were obese and not specific to T1D.", "Model-based analyses require specialized software and expertise." ], "source_type": "paper", "summary": "FNIH Biomarkers Consortium study standardizing MMTT and AST protocols and assessing reproducibility across glucose tolerance states. Provides detailed sampling schedules, meal composition, and model-based calculations for insulin secretion and sensitivity, enabling consistent beta-cell function assessment in trials.", "title": "Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of Beta-Cell Function", "url": "https://doi.org/10.2337/dc15-0931", "venue": "Diabetes Care", "year": 2016 }, { "assumptions": [ "Definitions are consensus-based and intended for trial reporting and clinical practice.", "Thresholds balance physiologic variation and practical monitoring limits." ], "authors": [ "Elizabeth R. Seaquist", "John Anderson", "Belinda Childs", "Philip Cryer", "Samuel Dagogo-Jack", "Lisa Fish", "Simon R. Heller", "Henry Rodriguez", "James Rosenzweig", "Robert Vigersky" ], "citation": "Elizabeth R. Seaquist; John Anderson; Belinda Childs et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013). https://doi.org/10.2337/dc12-2480", "claims": [ "Severe hypoglycemia requires assistance and may lack contemporaneous glucose measurement.", "An alert threshold of <=70 mg/dL is pragmatic for monitoring and prevention." ], "conclusions": [ "Uniform hypoglycemia definitions are necessary for consistent trial reporting and risk management." ], "contributions": [ "Standardizes hypoglycemia definitions and reporting categories.", "Provides clinical context for hypoglycemia risks and prevention." ], "future_work": [ "Further research on hypoglycemia outcomes and mitigation strategies.", "Refinement of definitions with improved CGM accuracy." ], "key_equations": [ "Alert value: glucose <= 70 mg/dL (<= 3.9 mmol/L).", "Severe hypoglycemia: event requiring assistance; recovery after glucose correction indicates low glucose etiology.", "Documented symptomatic hypoglycemia: symptoms with glucose <= 70 mg/dL." ], "limitations": [ "Consensus-based thresholds may shift with evolving technologies and evidence.", "Recommendations are general and require clinical judgment." ], "source_type": "paper", "summary": "Consensus workgroup report defining and classifying hypoglycemia in diabetes, emphasizing severe hypoglycemia requiring assistance and alert value thresholds for clinical reporting. Provides standardized definitions used in clinical trials and practice, and outlines implications and prevention strategies.", "title": "Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and the Endocrine Society", "url": "https://doi.org/10.2337/dc12-2480", "venue": "Diabetes Care", "year": 2013 }, { "assumptions": [ "Registry data pooled across eras with nonrandomized comparisons.", "Outcome definitions are consistent across participating sites." ], "authors": [ "Franca B. Barton", "Michael R. Rickels", "Rodolfo Alejandro", "Bernhard J. Hering", "Susan Wease", "Bashoo Naziruddin", "Jose Oberholzer", "Jonathon S. Odorico", "Mark R. Garfinkel", "Marcelo Levy", "Francois Pattou", "Thierry Berney", "Antonio Secchi", "Steve Messinger", "Peter A. Senior", "Paolo Maffi", "Andrew M. Posselt", "Peter G. Stock", "Dixon B. Kaufman", "Xunrong Luo", "Fouad Kandeel", "Edward Cagliero", "Nicole A. Turgeon", "Piotr Witkowski", "Ali Naji", "et al." ], "citation": "Franca B. Barton; Michael R. Rickels; Rodolfo Alejandro et al. Improvement in Outcomes of Clinical Islet Transplantation: 1999-2010. Diabetes Care (2012). https://doi.org/10.2337/dc12-0063", "claims": [ "Insulin independence at 3 years improved from 27% (1999-2002) to 44% (2007-2010).", "C-peptide >=0.3 ng/mL was retained longer in the most recent era.", "Freedom from severe hypoglycemia remained >90% across eras with graft function." ], "conclusions": [ "Clinical islet transplantation outcomes improved substantially from 1999-2010, supporting continued development toward licensure." ], "contributions": [ "Provides longitudinal benchmarks for islet transplant efficacy and safety.", "Links C-peptide persistence to reduced severe hypoglycemia and better HbA1c outcomes.", "Documents shifts in immunosuppression and procedural practices over time." ], "future_work": [ "Further trials to confirm efficacy under standardized protocols.", "Immunosuppression optimization and durability studies." ], "key_equations": [ "C-peptide graft function: fasting C-peptide >= 0.3 ng/mL; complete graft loss: fasting C-peptide undetectable with stimulated C-peptide <0.3 ng/mL.", "Insulin independence: >=14 consecutive days without exogenous insulin.", "HbA1c endpoint: <6.5% and/or drop >=2 percentage points.", "Fasting blood glucose target range: 60-140 mg/dL.", "Absence of severe hypoglycemia: no events requiring assistance." ], "limitations": [ "Registry data are observational with missing data and potential reporting lag.", "Era comparisons are confounded by evolving practices." ], "source_type": "paper", "summary": "Registry analysis (CITR) of 677 allogeneic islet transplant recipients from 1999-2010, showing improved insulin independence and graft function in later eras, sustained reductions in severe hypoglycemia, and evolving immunosuppression strategies. Provides historical benchmarks for outcomes and risks.", "title": "Improvement in Outcomes of Clinical Islet Transplantation: 1999-2010", "url": "https://doi.org/10.2337/dc12-0063", "venue": "Diabetes Care", "year": 2012 }, { "assumptions": [ "Single-arm design accepted for license-enabling trial.", "Patients already required immunosuppression for kidney graft.", "Portal vein infusion reflects standard islet delivery." ], "authors": [ "James F. Markmann", "Michael R. Rickels", "Thomas L. Eggerman", "Nancy D. Bridges", "Denise E. Lafontant", "Junaid Qidwai", "E. Donnall Thomas", "William R. Clarke", "Monica Kamoun", "Rodolfo Alejandro", "Melena D. Bellin", "et al." ], "citation": "James F. Markmann; Michael R. Rickels; Thomas L. Eggerman et al. Phase 3 Trial of Human Islet-After-Kidney Transplantation in Type 1 Diabetes. American Journal of Transplantation (2021). https://doi.org/10.1111/ajt.16174", "claims": [ "62.5% achieved the primary endpoint at day 365; HbA1c declined from ~8.1% to ~6.0%.", "SHEs were eliminated in most participants during year 1.", "Portal vein infusion and standardized PHPI manufacturing were used; kidney function remained stable." ], "conclusions": [ "Islet-after-kidney transplantation improves glycemic control and hypoglycemia outcomes without compromising kidney graft function." ], "contributions": [ "Extends PHPI efficacy evidence to islet-after-kidney population.", "Reports CGM TIR and hypoglycemia metrics post-transplant.", "Evaluates kidney graft safety under islet transplantation." ], "future_work": [ "Longer follow-up and comparative effectiveness versus modern technologies.", "Immunosuppression optimization to reduce sensitization." ], "key_equations": [ "Primary endpoint: HbA1c <= 6.5% or reduction >=1% AND freedom from SHEs from day 28-365.", "Key secondary endpoint: HbA1c <7.0% AND freedom from SHEs from day 28-365.", "TIR for CGM reporting: 54-180 mg/dL.", "Dose thresholds: >5,000 IEQ/kg first dose; >=4,000 IEQ/kg subsequent doses." ], "limitations": [ "Small sample size and open-label design.", "Some loss to follow-up by year 3." ], "source_type": "paper", "summary": "CIT06 phase 3 trial of purified human pancreatic islet transplantation in T1D patients with prior kidney transplant, using portal vein infusion and immunosuppression, showing improved HbA1c, elimination of severe hypoglycemia, and stable kidney graft function through 3 years. Provides CGM metrics and MMTT-derived C-peptide restoration.", "title": "Phase 3 Trial of Human Islet-After-Kidney Transplantation in Type 1 Diabetes", "url": "https://doi.org/10.1111/ajt.16174", "venue": "American Journal of Transplantation", "year": 2021 }, { "assumptions": [ "Harmonized SOPs yield comparable product quality across centers.", "Lot release criteria correlate with clinical performance." ], "authors": [ "Camillo Ricordi", "et al." ], "citation": "Camillo Ricordi; et al. et al. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes (2016). https://doi.org/10.2337/db16-0234", "claims": [ "75 PHPI lots for CIT-07 met prespecified identity, purity, potency, and safety criteria.", "No primary nonfunction was observed in recipients of the standardized product." ], "conclusions": [ "Standardized manufacturing across facilities is feasible and supports regulatory-grade islet cell product consistency." ], "contributions": [ "Defines manufacturing and QC standards enabling multicenter phase 3 trials.", "Provides detailed donor acceptance criteria and process controls.", "Demonstrates feasibility of standardized PHPI production." ], "future_work": [ "Refine potency assays and correlate with clinical outcomes.", "Apply manufacturing standards to next-generation islet products." ], "key_equations": [ "Islet dose: first infusion >= 5.0 x 10^3 IEQ/kg; subsequent >= 4.0 x 10^3 IEQ/kg.", "Viability: >= 70% viable islets per bag.", "Endotoxin: <= 5.0 EU/kg recipient body weight.", "Potency (GSIR): stimulation index > 1.", "Settled tissue volume: <= 7.5 mL per bag (<= 15 mL total)." ], "limitations": [ "Manufacturing outcomes may not directly translate to clinical outcomes in all settings.", "Potency assays require further validation for rapid lot release." ], "source_type": "paper", "summary": "Describes standardized manufacturing, QC, and lot release for purified human pancreatic islet products across eight facilities in the NIH CIT Consortium. Provides acceptance criteria, potency/viability thresholds, and manufacturing controls supporting phase 3 trials.", "title": "National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities", "url": "https://doi.org/10.2337/db16-0234", "venue": "Diabetes", "year": 2016 }, { "assumptions": [ "Single-arm open-label trials with historical controls can be acceptable for unstable T1D.", "Composite endpoints capture clinically meaningful benefit." ], "authors": [ "U.S. Food and Drug Administration" ], "citation": "U.S. Food and Drug Administration et al. Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products. FDA Guidance (2009). https://www.fda.gov/media/77497/download", "claims": [ "Composite endpoints combining HbA1c and hypoglycemia are acceptable for licensure.", "Eligibility should document severe hypoglycemia and absent C-peptide." ], "conclusions": [ "Standardized manufacturing and rigorous trial design are required to establish safety and efficacy of allogeneic islet products." ], "contributions": [ "Regulatory framework for islet cell product development.", "Defines recommended endpoints, dosing considerations, and follow-up expectations." ], "future_work": [ "Ongoing alignment of trial endpoints with emerging CGM metrics and outcomes." ], "key_equations": [ "Primary endpoint example: HbA1c <= 6.5% AND elimination of hypoglycemia.", "Eligibility: T1D >=5 years with absent or very low C-peptide (e.g., stimulated <0.3 ng/mL).", "Severe hypoglycemia defined as events requiring assistance." ], "limitations": [ "Nonbinding recommendations; specifics may evolve with new evidence." ], "source_type": "report", "summary": "FDA guidance outlining manufacturing, preclinical, and clinical trial considerations for allogeneic pancreatic islet cell products. Recommends composite primary endpoints, eligibility criteria, and long-term follow-up to support licensure and safety assessment.", "title": "Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products", "url": "https://www.fda.gov/media/77497/download", "venue": "FDA Guidance", "year": 2009 } ]